This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 111/24/3202    most recent CIRCULATIONAHA.104.510982v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ellenbogen, K. A. Search for Related Content PubMed PubMed Citation Articles by Ellenbogen, K. A. Related Collections Arrhythmias, clinical electrophysiology, drugs

(Circulation. 2005;111:3202-3208.)
© 2005 American Heart Association, Inc.

Arrhythmia/Electrophysiology

Trial to Evaluate the Management of Paroxysmal Supraventricular Tachycardia During an Electrophysiology Study With Tecadenoson

Kenneth A. Ellenbogen, MD; Gearoid O’Neill, MD; Eric N. Prystowsky, MD; John A. Camm, MD; Lixin Meng, MS, MPH; Hsiao Dee Lieu, MD; Markus Jerling, MD, PhD; Revati Shreeniwas, MD; Luiz Belardinelli, MD; Andrew A. Wolff, MD, for the TEMPEST Study Group^*

From the Medical College of Virginia, Richmond (K.A.E.); Regional Cardiology Associates, Sacramento, Calif (G.O.); Care Group, LLC, Indianapolis, Ind (E.N.P.); St George’s Hospital Medical School, London, UK (J.A.C); and CV Therapeutics, Palo Alto, Calif (L.M., H.D.L., M.J., R.S., L.B., A.A.W.).

Correspondence to Kenneth A. Ellenbogen, MD, FACC, Medical College of Virginia, 1200 E Marshall St, 3rd Floor, PO Box 980053, Richmond, VA 23298-0053. E-mail kellenbogen{at}pol.net

Received October 5, 2004; revision received February 23, 2005; accepted March 2, 2005.

Background— Tecadenoson is a potent selective A₁-adenosine receptor agonist with a dose-dependent negative dromotropic effect on the AV node. Tecadenoson terminates induced paroxysmal supraventricular tachycardia (PSVT) without the clinically significant side effects caused by stimulation of other adenosine receptors. This trial was designed to determine a safe and effective tecadenoson bolus for termination of electrophysiologically induced PSVT.

Methods and Results— Patients with a history of symptomatic PSVT and inducible PSVT at the time of a clinically indicated electrophysiology study were randomized into a multicenter, double-blind, placebo-controlled trial. Five 2-dose tecadenoson bolus regimens were evaluated versus placebo (75/150, 150/300, 300/600, 450/900, 900 µg/900 µg). The second bolus was administered only if PSVT persisted for 1 minute after the first bolus. Each tecadenoson regimen resulted in a significant therapeutic conversion rate compared with placebo (range, 50.0% to 90.3%, analysis of all patients dosed; n=181; P<0.0005). Conversion by the first bolus was dose related (range: placebo, 3.3% to 86.7% for 900 µg/900 µg). Time to conversion was dose dependent, with a median time of <1 minute for the 3 highest dose regimens. Postconversion arrhythmias were transient, requiring no additional treatment in 4 regimens (including placebo). Transient second- and third-degree heart block occurred at higher doses (300/600, 450/900, 900 µg/900 µg) and was supported with backup pacing when needed. No effect on blood pressure was observed. Ten patients with a history of asthma or chronic obstructive pulmonary disease tolerated tecadenoson without bronchospasm.

Conclusions— We identified an optimal tecadenoson regimen (300 µg/600 µg) that effectively and rapidly converted 90% (28 of 31) of PSVT patients to normal sinus rhythm with no significant adverse effects.

Key Words: adenosine • drugs • electrophysiology • tachyarrhythmias • tecadenoson

This article has been cited by other articles:

				I. Savelieva and J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace, June 1, 2008; 10(6): 647 - 665. [Abstract] [Full Text] [PDF]